FDA panel votes against approving Intellipharma’s opioid painkiller
(Reuters) – A panel of independent advisers to the U.S. Food and Drug Administration overwhelmingly concluded on Wednesday that there is not enough evidence to support approval of Intellipharmaceutics International Inc’s long-acting opioid painkiller.
FDA panel votes against ‘abuse-deterrent’ opioid with blue dye
FDA Committee Votes Down Approval Of Abuse-Deterrent Opioid
View original article
Powered by WPeMatico